# Prime Medicine Inc. (PRME)

Source: https://www.quantisnow.com/company/PRME
Generated: 2026-11-08T04:20:25.275Z

- Ticker: PRME
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2022
- SEC CIK: 0001894562

## Latest PRME news and filings

- 2026-10-05 12:00 UTC [Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease](https://www.quantisnow.com/insight/prime-medicine-announces-first-patient-dosed-in-global-phase-12-6735944)
- 2026-09-24 20:01 UTC [Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency](https://www.quantisnow.com/insight/prime-medicine-announces-us-fda-clearance-of-investigational-new-drug-6725306)
- 2026-09-03 12:00 UTC [Conference Announcement] [Prime Medicine to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/prime-medicine-to-participate-in-upcoming-investor-conferences-6704256)
- 2026-08-25 14:00 UTC [Analyst Coverage Resumed] [Chardan Capital Markets resumed coverage on Prime Medicine with a new price target](https://www.quantisnow.com/insight/chardan-capital-markets-resumed-coverage-on-prime-medicine-with-a-6693890)
- 2026-08-19 12:30 UTC [Analyst Coverage Initiated] [BMO Capital Markets initiated coverage on Prime Medicine with a new price target](https://www.quantisnow.com/insight/bmo-capital-markets-initiated-coverage-on-prime-medicine-with-a-6687918)
- 2026-08-06 12:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-prime-medicine-inc-6667501)
- 2026-08-06 12:02 UTC [SEC Form 8-K] [Prime Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/prime-medicine-inc-filed-sec-form-8-k-results-of-operations-6667491)
- 2026-08-06 12:00 UTC [Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/prime-medicine-reports-second-quarter-2026-financial-results-and-provides-6667385)
- 2026-07-23 20:05 UTC [Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease](https://www.quantisnow.com/insight/prime-medicine-announces-us-fda-clearance-of-investigational-new-drug-6646928)
- 2026-07-08 12:02 UTC [SEC Form 8-K] [Prime Medicine Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/prime-medicine-inc-filed-sec-form-8-k-other-events-6630942)
- 2026-07-08 12:00 UTC [Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics](https://www.quantisnow.com/insight/prime-medicine-announces-positive-resolution-to-arbitration-with-beam-therapeutics-6630888)
- 2026-06-29 12:52 UTC [Analyst Upgrade] [Prime Medicine upgraded by H.C. Wainwright with a new price target](https://www.quantisnow.com/insight/prime-medicine-upgraded-by-hc-wainwright-with-a-new-price-6618449)
- 2026-06-22 12:00 UTC [Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)](https://www.quantisnow.com/insight/prime-medicine-receives-us-fda-regenerative-medicine-advanced-therapy-rmat-6610065)
- 2026-06-18 12:00 UTC [Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease](https://www.quantisnow.com/insight/prime-medicine-announces-new-zealand-clearance-of-clinical-trial-application-6607934)
- 2026-06-08 20:21 UTC [SEC Form 4] [SEC Form 4 filed by Director Schenkein David P](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-schenkein-david-p-6593546)
- 2026-06-08 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Director Marrazzo Jeffrey D](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-marrazzo-jeffrey-d-6593537)
- 2026-06-08 20:19 UTC [SEC Form 4] [SEC Form 4 filed by Director Nelsen Robert](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-nelsen-robert-6593519)
- 2026-06-08 20:18 UTC [SEC Form 4] [SEC Form 4 filed by Director Kelly Michael Aaron](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kelly-michael-aaron-6593507)
- 2026-06-08 20:17 UTC [SEC Form 4] [SEC Form 4 filed by Director Foster-Cheek Kaye I](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-foster-cheek-kaye-i-6593495)
- 2026-06-08 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Chung Wendy](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-chung-wendy-6593450)
- 2026-06-08 20:13 UTC [SEC Form 4] [SEC Form 4 filed by Director Cahill Thomas](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cahill-thomas-6593427)
- 2026-06-08 20:10 UTC [SEC Form 8-K] [Prime Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/prime-medicine-inc-filed-sec-form-8-k-submission-of-matters-6593385)
- 2026-06-03 12:00 UTC [Conference Announcement] [Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference](https://www.quantisnow.com/insight/prime-medicine-to-present-at-goldman-sachs-47th-annual-global-6585856)
- 2026-05-28 12:00 UTC [Conference Announcement] [Prime Medicine to Present at Jefferies Global Healthcare Conference](https://www.quantisnow.com/insight/prime-medicine-to-present-at-jefferies-global-healthcare-conference-6576218)
- 2026-05-07 12:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-prime-medicine-inc-6537733)
- 2026-05-07 12:10 UTC [SEC Form 8-K] [Prime Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/prime-medicine-inc-filed-sec-form-8-k-results-of-operations-6537712)
- 2026-05-07 12:00 UTC [Leadership Update] [Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-6537648)
- 2026-04-23 12:38 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-prime-medicine-inc-6511860)
- 2026-04-23 12:35 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-prime-medicine-inc-6511856)
- 2026-04-18 00:26 UTC [SEC Form 4] [SEC Form 4 filed by Makhni Svetlana Ni](https://www.quantisnow.com/insight/sec-form-4-filed-by-makhni-svetlana-ni-6505613)
- 2026-04-18 00:25 UTC [SEC Form 3] [SEC Form 3 filed by new insider Makhni Svetlana Ni](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-makhni-svetlana-ni-6505611)
- 2026-04-16 12:15 UTC [SEC Form 8-K] [Prime Medicine Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/prime-medicine-inc-filed-sec-form-8-k-leadership-update-financial-6502405)
- 2026-04-16 12:00 UTC [Leadership Update] [Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer](https://www.quantisnow.com/insight/prime-medicine-appoints-svetlana-makhni-as-chief-financial-officer-6502315)
- 2026-03-12 12:54 UTC [Analyst Coverage Initiated] [Oppenheimer initiated coverage on Prime Medicine with a new price target](https://www.quantisnow.com/insight/oppenheimer-initiated-coverage-on-prime-medicine-with-a-new-price-6443756)
- 2026-03-05 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-prime-medicine-inc-6431216)
- 2026-03-03 13:41 UTC [SEC Form S-8] [SEC Form S-8 filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-prime-medicine-inc-6424092)
- 2026-03-03 13:32 UTC [SEC Form POS AM filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-prime-medicine-inc-6424082)
- 2026-03-03 13:19 UTC [SEC Form 10-K] [SEC Form 10-K filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-prime-medicine-inc-6423985)
- 2026-03-03 13:13 UTC [SEC Form POSASR filed by Prime Medicine Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-prime-medicine-inc-6423971)
- 2026-03-03 13:02 UTC [SEC Form 8-K] [Prime Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/prime-medicine-inc-filed-sec-form-8-k-results-of-operations-6423947)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PRME
- Earnings history: https://www.quantisnow.com/earnings/PRME
- Dividend history: https://www.quantisnow.com/dividends/PRME
- Insider transactions: https://www.quantisnow.com/insiders/PRME
- Options chain: https://www.quantisnow.com/options/PRME
- SEC 8-K filings only: https://www.quantisnow.com/company/PRME/8-k
- RSS and alerts for PRME: https://www.quantisnow.com/docs/rss-feeds.md